Skip to main content
Premium Trial:

Request an Annual Quote

FDA Issues Emergency Use Authorization for Gnomegen Coronavirus Test

NEW YORK — The US Food and Drug Administration on Monday granted Emergency Use Authorization to Gnomegen's COVID-19 RT-Digital PCR Detection kit for diagnosing SARS-CoV-2 infection.

According to the FDA, the in vitro diagnostic is designed for the qualitative detection of the nucleocapsid gene of the SARSCoV-2 virus in nasal, nasopharyngeal, and oropharyngeal swab specimens collected by healthcare providers. It runs on Thermo Fisher Scientific's Applied Biosystems QuantStudio 3D Digital PCR system.

The test is only authorized for use by CLIA-certified laboratories, which are required to report positive cases to health authorities, the FDA noted.

San Diego-based Gnomegen markets a digital PCR instrument and related cancer assays including ones for the detection of HER2 amplification and EGFR mutations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.